他汀类药物用于成人心血管疾病一级预防:美国预防医学工作组推荐声明
本推荐声明为USPSTF对其2016年推荐意见的更新,基于对证据的综述,评估他汀用于降低心血管疾病相关发病率、死亡率或全因死亡率的获益与危害。适用人群为≥40岁、无已知心血管疾病史且无心血管疾病症状和体征的成人。USPSTF以中等确定性得出结论:40~75岁无心血管疾病史、有≥1项危险因素(即血脂异常、糖尿病、高血压或吸烟)且估计10年心血管事件风险≥10%者,使用他汀至少具有中等净获益;同人群10年风险7.5%~<10%者至少具有小的净获益;≥76岁者证据不足以判断获益与危害的平衡。推荐意见为:对40~75岁、有≥1项危险因素且10年风险≥10%者处方他汀(B级推荐);对同人群10年风险7.5%~<10%者选择性提供他汀(C级推荐);≥76岁者证据不足(I声明)。
要点
- 40~75岁无心血管疾病史、有≥1项危险因素(血脂异常、糖尿病、高血压或吸烟)且10年心血管风险≥10%者,USPSTF推荐处方他汀(B级推荐)。
- 同人群10年风险7.5%~<10%者,USPSTF推荐选择性提供他汀(C级推荐),该组获益可能性小于10年风险≥10%者。
- ≥76岁无心血管疾病史者,USPSTF认为现有证据不足以评估启动他汀的获益与危害平衡(I声明)。
- 适用人群为≥40岁、无已知心血管疾病史且无心血管疾病症状和体征的成人。
- 美国每4例死亡中超过1例由心血管疾病导致,冠心病是单一首位死因,占心血管疾病归因死亡的43%。
适用人群与场景
- 适用人群:≥40岁、无已知心血管疾病史且无心血管疾病症状和体征的成人。
- 推荐分层人群:40~75岁、无心血管疾病史且有≥1项危险因素(即血脂异常、糖尿病、高血压或吸烟)者。
- ≥76岁、无心血管疾病史者:证据不足以评估启动他汀的获益与危害平衡(I声明)。
诊断标准与关键阈值
- 风险评估阈值:估计10年心血管事件风险≥10%为推荐处方他汀的阈值(B级推荐)。
- 估计10年心血管事件风险7.5%~<10%为选择性提供他汀的阈值(C级推荐)。
- 危险因素标准:≥1项心血管疾病危险因素,即血脂异常、糖尿病、高血压或吸烟。
处置流程与药物剂量
- 对40~75岁、无心血管疾病史、有≥1项危险因素且估计10年心血管事件风险≥10%者,临床医生应处方他汀用于心血管疾病一级预防(B级推荐)。
- 对40~75岁、无心血管疾病史、有≥1项危险因素且估计10年心血管事件风险7.5%~<10%者,临床医生应选择性提供他汀用于心血管疾病一级预防(C级推荐);该组获益可能性小于10年风险≥10%者。
- 对≥76岁、无心血管疾病史者,现有证据不足以评估启动他汀用于心血管疾病事件和死亡率一级预防的获益与危害平衡(I声明)。
研究设计与关键结果
- USPSTF委托对证据进行综述,评估他汀降低心血管疾病相关发病率或死亡率或全因死亡率的获益与危害,以更新其2016年推荐。
- USPSTF以中等确定性得出结论:40~75岁无心血管疾病史、有≥1项危险因素且估计10年心血管事件风险≥10%者,使用他汀至少具有中等净获益。
- USPSTF以中等确定性得出结论:40~75岁无心血管疾病史、有≥1项危险因素且估计10年心血管事件风险7.5%~<10%者,使用他汀至少具有小的净获益。
- USPSTF认为证据不足以确定≥76岁无心血管疾病史成人使用他汀用于心血管疾病事件和死亡率一级预防的获益与危害平衡。
证据类型、等级与局限
- 证据类型:USPSTF推荐声明,基于委托的证据综述。
- 推荐等级:10年风险≥10%组为B级推荐;10年风险7.5%~<10%组为C级推荐;≥76岁组为I声明。
- 确定性:对10年风险≥10%组和7.5%~<10%组的净获益结论均为中等确定性。
- 局限:原文未报告局限性
对床旁实践的改变
- 对40~75岁无心血管疾病史、有≥1项危险因素(血脂异常、糖尿病、高血压或吸烟)者,应估算10年心血管事件风险并据此分层:≥10%者处方他汀(B级推荐),7.5%~<10%者选择性提供他汀(C级推荐)。
- 对≥76岁无心血管疾病史者,USPSTF认为证据不足以评估启动他汀的获益与危害平衡(I声明),不应将上述40~75岁人群的推荐直接外推至该人群。
指南或共识出处
- USPSTF(美国预防医学工作组)他汀类药物用于成人心血管疾病一级预防推荐声明,JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cardiovascular disease (CVD) is the leading cause of morbidity and death in the US and is the cause of more than 1 of every 4 deaths. Coronary heart disease is the single leading cause of death and accounts for 43% of deaths attributable to CVD in the US. In 2019, an estimated 558 000 deaths were caused by coronary heart disease and 109 000 deaths were caused by ischemic stroke.
OBJECTIVE: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on the benefits and harms of statins for reducing CVD-related morbidity or mortality or all-cause mortality.
POPULATION: Adults 40 years or older without a history of known CVD and who do not have signs and symptoms of CVD.
EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 to 75 years with no history of CVD and who have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD event risk of 10% or greater has at least a moderate net benefit. The USPSTF concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 to 75 years with no history of CVD and who have 1 or more of these CVD risk factors and an estimated 10-year CVD event risk of 7.5% to less than 10% has at least a small net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of statin use for the primary prevention of CVD events and mortality in adults 76 years or older with no history of CVD.
RECOMMENDATION: The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD risk of 10% or greater. (B recommendation) The USPSTF recommends that clinicians selectively offer a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more of these CVD risk factors and an estimated 10-year CVD risk of 7.5% to less than 10%. The likelihood of benefit is smaller in this group than in persons with a 10-year risk of 10% or greater. (C recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older. (I statement).
参考来源
- Mangione CM, Barry MJ, Nicholson WK, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022. PMID: 35997723. doi:10.1001/jama.2022.13044
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。